Dimitrios Diamandidis
Hematology & Oncology · Las Vegas, NVNPI 1063457737
Payments from drug & device makers
Across 680 payments — averaging $25.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$2K
- AstraZeneca$2K
- Novartis$2K
- Astellas Pharma US Inc$1K
- Incyte Corporation$1K
- Amgen$803
- plus $9K from 54 others
Across 2 payments — averaging $750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Onquality Pharmaceuticals (USA) LLC$2K
What the payments were for
- Consulting fees$1,3658%
- Food & beverage$13,37576%
- Education$1,72210%
- Other$1,1827%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,643 in reported general payments places this provider in the 45th percentile of 82 hematology & oncology providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $10,726 |
| Letrozole | 41 | $501 |
| Anastrozole | 14 | $164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $308 | $10,72613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 82 hematology & oncology providers in Nevada.
Other hematology & oncology in Las Vegas
- Edwin KingsleyLas Vegas$9.2M
- Nicholas VogelzangLas Vegas$8.3M
- Oscar GoodmanLas Vegas$6M
- Khawaja JahangirLas Vegas$2.5M
- Carolyn MulroneyLas Vegas$1.5M
- Wolfram SamlowskiLas Vegas$1.1M
- Anuradha ThummalaLas Vegas$736K
- Grzegorz ObaraLas Vegas$668K
- Aaron GoodmanLas Vegas$480K
- Vikas GuptaLas Vegas$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.